Recent Updates
Recently added Catalysts
ALLR Negative Sentiment Score: 25/100

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Key Takeaway: Allarity Therapeutics, Inc. is under investigation by Bronstein, Gewirtz & Grossman, LLC due to a Wells Notice issued by the SEC. This notice relates to the company's disclosures about its New Drug Application for Dovitinib and suggests potential violations of federal securities laws. Furthermore, three of Allarity's former officers have also received Wells Notices. As a result of this development, Allarity's stock price has declined, prompting an investigation into the matter.

Market Sentiment Analysis

CONCERNS & RISKS

  • Allarity received a 'Wells Notice' from the SEC regarding potential violations of federal securities laws.
  • The SEC has made a preliminary determination to recommend filing an enforcement action against the company.
  • Three former officers of Allarity also received Wells Notices related to the same conduct.
  • Following the news of the Wells Notice, Allarity's stock price dropped.

Full Press Release Details

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. (“Allarity” or “the Company”) (NASDAQ: ALLR). Investors who purchased Allarity securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ALLR.
Investigation Details
On July 22, 2024, Allarity filed a current report on Form 8-K with the SEC and disclosed that, “Allarity Therapeutics, Inc. (the ‘Company’) received a ‘Wells Notice’ from the Staff of the U.S. Securities and Exchange Commission (the ‘SEC’) relating to the Company’s previously disclosed SEC investigation.” Allarity also revealed that “[t]he Wells Notice relates to the Company’s disclosures regarding meetings with the United States Food and Drug Administration (the ‘FDA’) regarding the Company’s NDA [New Drug Application] for Dovitinib or Dovitinib-DRP,” and that “Allarity also understands that three of its former officers received Wells Notices from the SEC relating to the same conduct.” Further, “[t]he Wells Notice informed the Company that the SEC Staff has made a preliminary determination to recommend that the SEC file an enforcement action against the Company that would allege certain violations of the federal securities laws.” Following this news, Allarity stock price dropped.
If you are aware of any facts relating to this investigation or purchased Allarity securities, you can assist this investigation by visiting the firm’s site: bgandg.com/ALLR. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Tags

Frequently Asked Questions

What is the investigation about Allarity Therapeutics?

The investigation concerns potential claims related to Allarity’s SEC disclosures.

What is a Wells Notice?

A Wells Notice indicates the SEC’s intent to recommend enforcement actions.

How did Allarity's stock react to the news?

Following the announcement, the stock price of Allarity dropped significantly.

Is it free to participate in the investigation?

Yes, there is no cost to participate; fees are contingent on success.

Who can investors contact for more information?

Investors can contact Peretz Bronstein or Nathan Miller at 332-239-2660.

Last updated: Jul 26, 2024